3-49422261-C-T
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2
The ENST00000273588.9(AMT):c.101G>A(p.Arg34His) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000622 in 1,614,046 control chromosomes in the GnomAD database, including 4 homozygotes. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R34C) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000273588.9 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
AMT | NM_000481.4 | c.101G>A | p.Arg34His | missense_variant | 2/9 | ENST00000273588.9 | NP_000472.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
AMT | ENST00000273588.9 | c.101G>A | p.Arg34His | missense_variant | 2/9 | 1 | NM_000481.4 | ENSP00000273588 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000545 AC: 83AN: 152222Hom.: 1 Cov.: 32
GnomAD3 exomes AF: 0.000804 AC: 202AN: 251204Hom.: 0 AF XY: 0.000803 AC XY: 109AN XY: 135816
GnomAD4 exome AF: 0.000629 AC: 920AN: 1461706Hom.: 3 Cov.: 31 AF XY: 0.000619 AC XY: 450AN XY: 727158
GnomAD4 genome AF: 0.000551 AC: 84AN: 152340Hom.: 1 Cov.: 32 AF XY: 0.000618 AC XY: 46AN XY: 74492
ClinVar
Submissions by phenotype
Non-ketotic hyperglycinemia Uncertain:1Benign:2
Likely benign, no assertion criteria provided | clinical testing | Natera, Inc. | Dec 16, 2019 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 10, 2023 | Variant summary: AMT c.101G>A (p.Arg34His) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00063 in 1461706 control chromosomes, predominantly at a frequency of 0.0026 within the Middle Eastern subpopulation in the gnomAD database, and it is present in three homozygotes across all subpopulations. The observed variant frequency is 1.86-fold of the estimated maximal expected allele frequency for a pathogenic variant in AMT causing Glycine Encephalopathy (Non-Ketotic Hyperglycinemia) (0.0026 vs. 0.0014), strongly suggesting that the variant is a benign polymorphism found primarily in populations of Middle Eastern origin. To our knowledge, no occurrence of c.101G>A in individuals affected with Glycine Encephalopathy (Non-Ketotic Hyperglycinemia) and no experimental evidence demonstrating its impact on protein function have been reported. Three submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. One classified the variant as uncertain significance, and two classified the variant as benign/likely benign. Based on the evidence outlined above, the variant was classified as likely benign. - |
AMT-related disorder Benign:1
Benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | May 08, 2024 | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at